Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of TNO155 in combination with spartalizumab or ribociclib in advanced solid tumors
jRCT2080224928Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of batoprotafib, spartalizumab and ribociclib in Non-hematologic malignancy, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 2 more (2 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of TNO155 + spartalizumab and TNO155 + ribociclib. Started Oct 2019; status: completed.
02
Drugs
batoprotafibspartalizumabribociclib
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080224928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224928.